Deal Snapshot
Gilead Sciences to Acquire UK Biotech MiroBio for USD 405m
Friday 05 August 2022

California-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) and MiroBio, has agreed to acquire UK-based clinical-stage biotechnology company MiroBio for approximately USD 405m in cash, the company said.

Under the terms of the agreement, Gilead will acquire all of the outstanding share capital of MiroBio.

Date Published: 05/08/2022